Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00BZZ
|
||||
| Former ID |
DIB003986
|
||||
| Drug Name |
PF-4603629
|
||||
| Synonyms |
BRX-1177; PF-04603629; Exendin-4 transferrin fusion protein (diabetes), Pfizer/BioRexis
|
||||
| Company |
Biorexis Pharmaceutical Corp
|
||||
| Target and Pathway | |||||
| Target(s) | Glucagon-like peptide 1 receptor | Target Info | Modulator | [530376], [532841] | |
| References | |||||
| Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
| Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | ||||
| Ref 551186 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | ||||
| Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
| Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.